Literature DB >> 23566753

Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.

Bunchoo Pongtanakul, Vip Viprakasit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23566753     DOI： 10.1016/j.bcmd.2013.03.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN： 1079-9796            Impact factor:   3.039


× No keyword cloud information.
  3 in total

Review 1.  Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review.

Authors:  Tirin Babu; George Mathew Panachiyil; Juny Sebastian; Mandyam Dhati Ravi
Journal:  Indian J Pharmacol       Date:  2020 Nov-Dec       Impact factor: 1.200

2.  Long-Term Effectiveness, Safety, and Tolerability of Twice-Daily Dosing with Deferasirox in Children with Transfusion-Dependent Thalassemias Unresponsive to Standard Once-Daily Dosing.

Authors:  Jassada Buaboonnam; Chayamon Takpradit; Vip Viprakasit; Nattee Narkbunnam; Nassawee Vathana; Kamon Phuakpet; Kleebsabai Sanpakit; Bunchoo Pongtanakul
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-11-01       Impact factor: 2.576

Review 3.  Clinical pharmacology of deferasirox.

Authors:  Chiaki Tanaka
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 5.577
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.